Drug Development Service Targeting TAM Recruitment Blocking

TAMs Recruitment Blocking with Great Significance

Tumor-associated macrophages (TAMs) are commonly found in the tumor microenvironment (TME), making up approximately 30 to 50% of stromal cells. The number of intratumoral TAMs increases as the tumor progresses because of self-proliferation, recruitment, and differentiation from circulating inflammatory Ly6C+CCR2+ monocytes. However, higher levels of TAMs are usually associated with the progression of cancer and an unfavorable prognosis. Therefore, blocking TAM recruitment is significant for the downregulation of TAMs and inhibiting cancer progression.

Fig.1 TAM-based therapeutic options for liver cancer.¹

Our Drug Development Service Targeting TAM Recruitment Blocking

Creative Biolabs succeeded in providing a cost-effective drug development service targeting TAM recruitment blocking to assist drug development in cancer therapy. In our service, we target the signals involved in the recruitment of TAM and tumor development to discover new drugs that block TAM recruitment. Moreover, we can customize our drug development services in accordance with customers' needs to develop diverse drug types such as antibody drugs, small molecule drugs, antibody-conjugate drugs, and so on. Promising here, we will deliver a comprehensive, customized, and excellent service to satisfy every customer around the world.

We provide several targets including but not limited to the following with the aim to support the global customer' diverse needs:

Highlight Features

• Diverse targets provide
• Multiple drug types to choose from
• Fast timelines
• Experienced expert team support
• One-stop customized services

Representative Data

Background: TAMs commonly release immunosuppressive cytokines, which often leads to the failure of ICB treatment. In order to enhance the effectiveness of ICB in cancer patients, it is necessary to manipulate the quantity and activity of TAMs in the TME. This manipulation has the potential to establish a biological basis for improving the therapeutic response of ICB. The research discovered novel approaches for treating lung cancers using immunotherapy, which gives us a deeper understanding of TAMs within the immunosuppressive microenvironment.

Methods: The anticancer efficacy of Rhizoma Coptidis (RC) was examined in animal models with Lewis lung carcinoma (LLC) xenografts. The flow cytometry method was used to analyze the effect of RC on M2 macrophage accumulation. In the study, the expression of LTA4H and BLT1, as well as the influence of leukotriene B4 (LTB4) signaling blocking on M2 macrophage recruitment were tested by western blot, transwell migration assays.

Results: This research reveals that RC can sensitize lung cancer to immunotherapy by inhibiting LTB4 signaling-mediated TAMs. In addition, the study implies that RC has the potential of anti-tumor immunity, which offers a justification for the prospective integration of RC with immunotherapies as a therapeutic approach to cancer.

Fig.2 LTB4 signaling inhibition combined with anti-PD-L1 antibody leads to tumor growth suppression.²

If you are interested in our drug development service targeting TAM recruitment blocking, please feel free to get in touch with us to know more details.

References

1. Cheng, Kun, et al. "Tumor‐associated macrophages in liver cancer: from mechanisms to therapy." Cancer Communications 42.11 (2022): 1112-1140.
2. Yan, Jiangna, et al. "Blocking LTB4 signaling-mediated TAMs recruitment by Rhizoma Coptidis sensitizes lung cancer to immunotherapy." Phytomedicine 119 (2023): 154968.